Abstract |
Although autologous bone marrow transplantation (ABMT) following purging with 4-hydroperoxycyclophosphamide (4HC) has been effective for some adults with acute non- lymphoblastic leukemia ( ANLL), there are few data on ABMT for children. We have performed ABMT for 13 patients (median age, 5 years) with ANLL in second remission. Bone marrow was treated ex vivo with 4HC to kill residual leukemic cells. In order to enhance the anti-leukemic effect of 4HC, exogenous red blood cells were eliminated from the marrow/4HC mixture. All patients were conditioned for transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg), followed by infusion of the 4HC treated marrow. Eleven of 13 patients had complete hematologic reconstitution; there were no transplant-related deaths. Five patients relapsed at 2, 4, 5, 6 and 6 months post-BMT. Eight patients are disease-free survivors; the median time for survival is 24 months, with a projected disease-free survival of 61%. ABMT is a safe and efficacious treatment modality for children with ANLL in second remission. Our results suggest that the disease-free survival for pediatric patients may be superior to that seen in adults.
|
Authors | C Lenarsky, K Weinberg, J Petersen, J Nolta, J Brooks, G Annett, D Kohn, R Parkman |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 6
Issue 6
Pg. 425-9
(Dec 1990)
ISSN: 0268-3369 [Print] England |
PMID | 2097012
(Publication Type: Journal Article)
|
Chemical References |
- Cyclophosphamide
- Busulfan
- perfosfamide
|
Topics |
- Actuarial Analysis
- Adolescent
- Adult
- Bone Marrow Transplantation
(methods)
- Busulfan
(administration & dosage)
- Child
- Child, Preschool
- Cyclophosphamide
(administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
- Evaluation Studies as Topic
- Graft Survival
- Humans
- Infant
- Leukemia, Myeloid, Acute
(pathology, surgery)
- Neoplastic Stem Cells
(drug effects)
- Remission Induction
- Transplantation, Autologous
|